Nektar Therapeutics - 53 Year Dividend History | NKTR
Historical dividend payout and yield for Nektar Therapeutics (NKTR) since 1971. The current TTM dividend payout for Nektar Therapeutics (NKTR) as of November 20, 2024 is $0.00. The current dividend yield for Nektar Therapeutics as of November 20, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Drug Manufacturing |
$0.186B |
$0.090B |
|
Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
